The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $623 Tisíc dollars as of 22 September 2015. James P owns over 175,000 units of Regenxbio Inc stock worth over $622,790 and over the last 9 years James sold RGNX stock worth over $0.
James has made over 1 trades of the Regenxbio Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently James bought 175,000 units of RGNX stock worth $3,850,000 on 22 September 2015.
The largest trade James's ever made was buying 175,000 units of Regenxbio Inc stock on 22 September 2015 worth over $3,850,000. On average, James trades about 175,000 units every 0 days since 2015. As of 22 September 2015 James still owns at least 49,000 units of Regenxbio Inc stock.
You can see the complete history of James P stock trades at the bottom of the page.
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas a Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Regenxbio Inc executives and other stock owners filed with the SEC include: